Horizant is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. It is not recommended for patients who are required to sleep during the daytime
The first shipment of the product has triggered a milestone payment under the license, manufacturing and supply agreement with Precision Dose and its wholly owned subsidiary TAGI Pharma.
The agreement was made for the discovery of new cationic lipids employed in lipid nanoparticles (LNPs) for the systemic delivery of RNAi therapeutics. Alnylam has funded the research
The company has filed the marketing applications on the basis of the results from two 26-week Phase 2 studies evaluating Soliris as a treatment for adult and adolescent
Following the merger, the combined entity will be known as Astex Pharmaceuticals and will focus on oncology drug discovery, development and commercialization. Pursuant to the terms of the
The global Phase III trial for Multikine was started in the US in late December 2010. CEL-SCI expects to commence the trial in other countries around the world
e-MD was selected based on their affordability, ePrescribing capability, CCHIT certification, ability to interface with a State health information exchange (HIE) system, and system functionality and benefit to
As per the agreement, KellBenx is expected to get worldwide rights for the commercialization of the antibodies which allow the extraction of clinically relevant information from maternal blood
Funding is in the form of one SBIR Phase 1 award titled ‘effects of P-188 on respiratory function and diaphragm degeneration in the mdx mouse’ and STTR phase
Rivaroxaban is a novel oral anticoagulant being evaluated for the prevention and treatment of a broad range of disorders in which blood clotting plays a major role. Rivaroxaban
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.